Síndrome antifosfolípide e diabetes mellitus na gestação
Palabras clave:
diabetes mellitus, diabetes gestacional, tromboembolismo, sindrome antifosfolipidicaResumen
O diabetes mellitus é uma doença metabólica que, quando presente em mulheres grávidas, cursa com maior risco materno e fetal, tanto em casos de diabetes gestacional como pré-gestacional. A síndrome antifosfolípide consiste na presença de anticorpos antifosfolípides e complicações clínicas, com pior prognóstico gestacional e maior número de perdas fetais. A associação do diabetes mellitus com a síndrome antifosfolípide é frequente. A presença de anticorpos antifosfolípides em gestantes diabéticas é alta, podendo aumentar o risco de doenças oclusivas vasculares, ocasionando maior morbidade materno-fetal. Desta forma, destacamos a importância da propedêutica diagnóstica da síndrome antifosfolípide em gestantes diabéticas que forem admitidas ao pré-natal, pois se os anticorpos estiverem presentes, as gestantes deverão ser tratadas de forma a evitar o comprometimento da vitalidade materna e fetal.
Descargas
Citas
Freinkel N. Gestational Diabetes 1979: phylosophycal and praticai aspects of a major public health problem. Diabetes Care 1998; 3:399.
Kilvert JA, Nicholson HD, Wright AD. Ketoacidose in diabetic pregnancy. Diabetic Med 1993; 10:278-81.
Dias EP. Consenso sobre diabetes gestational. Arq Bras Endocrinol Metab 1999; 43(2): 148-50.
White P. Pregnancy complicating diabetes. Am J Med 1949; 7:609- 16.
Moore TR. Diabetes in pregnancy maternal fetal medicine: principies and practice. Philadelphia: WB Saunders; 1999. p.964-95.
Tamás G, Kerenyi Z. Gestational diabetes: current aspects on pathogenesis and treatment. Exp Clin Endocrinol Diabetes 2001; 109 Suppl 2 :400-11.
Schwartz R, Gruppuso PA, Petzold K, Brambilla D, et ai. Hiperinsulinemia and macrossomia in the fetus of the diabetic mother. Diabetes Care 1994; 17(7):640-8.
Vaarasmaki M, Anttila M, Pirttiaho H, Hartikainen AL. Are recurrent pregnancies a risk in Type 1 diabetes? Acta Obstet Gynecol Scand 2002; 81(12):1110-5.
Diamond MP, Shaw DM, Hester RA, Vaughn WK, Cotton RB, Boehm FH. Complication of insulin-dependent diabetic pregnancies by preeclampsia and/ or chronic hypertension: analysis of outcome. Am J Perinatol 1985; 2(4):263-7
Vaaramaki M, Gissler M, Riyvanen A, Hartikainen AL. Congenital anomalies and first life year surveillance in Type I diabetic births. Diabetic Med 2002; 19(7):589-93
Lepercq J, Taupin P, Dubois-Laforque D, Duranteau L, Lahiou N, Boitard C, et ai. Heterogeneity of fetal growth in type 1 diabetic pregnancy. Diabete Metab 2001; 27(3):339-44.
Boddi M, Prisco D, Fedi S, Cellai AP, Liotta AA, Paretti E, et ai. Antiphospholipid antibodies and pregnancy disorders in womem with lnsulin-dependent diabetes. Tromb Res 1996; 82(3):207-16.
Triplett DA, Coulam CB, Faulk WP, Mcintyre JA Obstetrica complications associated with antiphospholipid antibodies. lmmunological Obstetrics. London: Norton Medical Books; 1992. p. 377- 403.
Galtier-Dereure F, Biron C, Vies M, Bourgeois V,Schved JF, Bringer J. Vascular complications of diabetes mellitus: what role for phospholipids-binding antibodies7 Lupus 1998; 7:469-74.
Kareria MV, Vishwanathan C. A preliminary study of antiphospholipid antibodies in 50 cases of bod obstetric history J Assoe Physicians lndia 1999; 47(7):669-72
Hadi HA, Treadwell EL. Lupus anticoagulant and anticardiolipin antibodies in pregnancy: a review. lmmunochemistry and clinicai implications. Obstet Gynecol Surv 1990; 45(11):780-5.
Arvieux J, Hachulla E. Antiphospholipid syndrome. Ann Cardiol Angeiol (Paris) 2002; 51 (3): 146-51.
Drout L. Venous thromboembolic pathology new acquired risk factors or new data on acquired risk factors. Arch Mal Coeur 2001; 94 Suppl 11: 1318-26.
Triplett D A. Assays for detection of antiphospholipid antibodies. Lupus 1994; 3: 281- 7.
Uszynski M, Uszynski W. Antiphospholipid syndrome in obstetrics-a new version of criteria, pathomechanism and the prophylaxis. Ginakol Pol 2002; 73(6):553-66.
Chamley LW. Antiphospholipid antibodies: biological basis and prospects for treatment. J Reprod lmmunol 2002; 57(1-2): 185.
Feinstein DL, Rapaport SI. Acquired inhibitors of blood coagulation: progress in hemostasis and thrombosis. New York: Guine e Straton; 1992. p. 75.
Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinicai thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002; 41 (8):924-9.
Best IM, Anyadike NC, Harvey L, Bumpers MD. The antiphospholipid syndrome in a teenager with miscariages, thrombosis, and diabetes mellitus. Am Surg 2000; 66(8):748-50.
Lubbe WF, Butler WS, Palmer SJ, Liggins GC. Lupus anticoagulant in pregnancy. Br J Obstet Gynaecol 1984; 91 :357-63.
Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992; 80(4):614-20.
Nash MJ, Camilleri RS, Liesner R, Mackie J, Machin SJ, Cohen H. Paradoxical association between the 316 Trp to Ser beta 2-glycoprotec 1 (Beta2GPI) polymorphism and anti-Beta2GPI antibodies. Br J Haematol 2003; 120(3):529-31.
lnbar O, Blanck M, Faden D, Tincani A, Lorber M, Shoenfeld Y Prevention of fetal loss in experimental antiphospholipid syndrome by low-molecular-weight heparin. Am J Obstet Gynecol 1993; 169:423-6.
Mcintyre JA, Taylor CG, Torry OS, Wagenknecht DR, Wilson J, Faulk WP Heparin and pregnancy in women with a history of repeated miscarriages. Haemostasis 1993; 23 Suppl 1 :202-11.
